ArticleClinical and translational medicine2022

YTHDF2 promotes intrahepatic cholangiocarcinoma progression and desensitises cisplatin treatment by increasing CDKN1B mRNA degradation.

Chen-Song Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.